JR Central and Gaudi Clinical ship cells by Shinkansen parcel service

The JR Central group and Gaudi Clinical began transporting cells and processed cell products for regenerative medicine on August 17, 2026, using Tokaido Mach Service (東海道マッハ便), the parcel service that runs on the Tokaido Shinkansen. The service extends Gaudi Clinical's regenerative medicine supply area, which had been limited to the Tokyo metropolitan area, to the Nagoya and Osaka areas.

The companies give the reason. Regenerative medicine comes with strict time limits from the collection of cells to their arrival at a cell processing facility and the start of manufacturing. Until now, the partner clinic that collects the cells and the processing facility had to be in the same area. The Shinkansen offers speed and punctuality, plus a low-vibration ride, for logistics in which time and quality conditions are tight.

What looks like a delivery story is really about where a cell processing facility can be built. Cells keep metabolizing after collection. As time passes, viability falls, the cells' state shifts, and manufacturing itself can fail. Developers set an upper limit through hold-time studies and can only place facilities within it. In effect, part of the manufacturing process has been tied to geography.

Vibration is named for a reason. Cell suspensions in transit face both vibration and temperature changes. When liquid sloshes in a container, the gas-liquid interface creates stress, and long exposure can lead to aggregation or membrane damage, the same family of effects as shear in a bioreactor. Road transport varies with each route's surface. A train runs the same line at the same speed, so the vibration history is easier to reproduce, and that matters as much as temperature if transport is treated as part of the process.

Gaudi Clinical has also announced a vacuum-insulated cell transport container developed with Tiger Corporation. The container holds temperature, and the rail route secures time and vibration. Records showing that conditions were met, and chain of identity at every handover, are still needed. Riding on an existing parcel service means building those procedures around its framework.

A wider supply area changes the economics. More patients per facility raises utilization, which drives cell therapy costs. Fewer regional facilities also means fewer technology transfers and comparability studies. The flip side is that transport becomes a single point of failure: a disrupted timetable can stop manufacturing.